从研发投入总量看，2022年，中国研发经费（R&D）投入规模首次突破3万亿元大关，仅次于美国，位居世界第二。其中，基础研究经费支出为1951亿元，占全部研发经费的比重为6.32%，相较十年前的4.8%，已是一个很大的提升，但仍远低于主要发达国家15%~25%的平均水平。王贻芳认为，中国基础研究的问题，一方面与总体的投入比例不足有关，更关键的症结在于，6.32%的经费也没有得到相对合理的分配，造成经费的使用效益不高。

zhongguozhongyaoxiehuizaiqianshu7yue8ridefawenzhongtidao，duiyaocaishichangxingqingyouqishisuoxucaigouyaocaipinzhongdeshichangxingqingdengjinxingmiqiegenzong，jishitiaozhengzhongyaoyinpianhezhongchengyaoshengchanjihua。tongshi，jianyidazhongxingqiyeyouqishipinpai、youzhiqiyeyinglvxianxingdong，dazaozhongyaoquanchanyelianzhiliangguankongtixi，jianlizhongyaocaizhiliangzhuisutixi，cujinchanxiaozhijieduijie，jinliangjianshaozhongjianchaozuohuanjie。中(zhong)国(guo)中(zhong)药(yao)协(xie)会(hui)在(zai)前(qian)述(shu)7(7)月(yue)8(8)日(ri)的(de)发(fa)文(wen)中(zhong)提(ti)到(dao)，(，)对(dui)药(yao)材(cai)市(shi)场(chang)行(xing)情(qing)尤(you)其(qi)是(shi)所(suo)需(xu)采(cai)购(gou)药(yao)材(cai)品(pin)种(zhong)的(de)市(shi)场(chang)行(xing)情(qing)等(deng)进(jin)行(xing)密(mi)切(qie)跟(gen)踪(zong)，(，)及(ji)时(shi)调(tiao)整(zheng)中(zhong)药(yao)饮(yin)片(pian)和(he)中(zhong)成(cheng)药(yao)生(sheng)产(chan)计(ji)划(hua)。(。)同(tong)时(shi)，(，)建(jian)议(yi)大(da)中(zhong)型(xing)企(qi)业(ye)尤(you)其(qi)是(shi)品(pin)牌(pai)、(、)优(you)质(zhi)企(qi)业(ye)应(ying)率(lv)先(xian)行(xing)动(dong)，(，)打(da)造(zao)中(zhong)药(yao)全(quan)产(chan)业(ye)链(lian)质(zhi)量(liang)管(guan)控(kong)体(ti)系(xi)，(，)建(jian)立(li)中(zhong)药(yao)材(cai)质(zhi)量(liang)追(zhui)溯(su)体(ti)系(xi)，(，)促(cu)进(jin)产(chan)销(xiao)直(zhi)接(jie)对(dui)接(jie)，(，)尽(jin)量(liang)减(jian)少(shao)中(zhong)间(jian)炒(chao)作(zuo)环(huan)节(jie)。(。)